Pharmacogenomics in the treatment of epilepsy.
Genetic variability has recently been implicated in the development of familial epilepsy syndromes and in heterogeneous responses of epilepsy patients to drug treatment. Mutations in distinct proteins have been shown to underlie the development of epilepsy, increase propensity for drug resistance, and alter drug metabolism. Improved understanding of how individual genetic variability may alter the efficacy of pharmacological therapeutic interventions is an important and timely goal. The investigation of relationships between genotype and patient responses to drug treatment is termed pharmacogenomics.
Clancy
Colleen E
CE
Department of Pharmacology, Columbia University, College of Physicians and Surgeons, 630 W. 168th Street, New York, NY 10032, USA. rsk20@columbia.edu
Kass
Robert S
RS
D000818:Animals; D000927:Anticonvulsants / Q000494:pharmacology / Q000627:therapeutic use*; D004827:Epilepsy / Q000188:drug therapy* / Q000235:genetics*; D006801:Humans; D010597:Pharmacogenetics / Q000379:methods*; D011110:Polymorphism, Genetic / Q000187:drug effects / Q000235:genetics
D000927:Anticonvulsants